A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A

联合疗法加西妥昔单抗治疗 HIV 相关 A 患者的 II 期试验

• 批准号: 8167098
• 负责人: RONALD T. MITSUYASU
• 金额: $ 1.05万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167098
• 关键词: Acquired Immunodeficiency Syndrome; Anus; CD4 Lymphocyte Count; Cetuximab; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Cytology; Development; Failure; Funding; Grant; HIV; Human Papillomavirus; Incidence; Infection; Institution; Malignant neoplasm of anus; Phase; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Viral Load result

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aim: To detect whether the addition of cetuximab to standard chemoradiation reduces the local failure rate by at least 50% Secondary Aims: 1) To characterize the effect of CMT plus cetuximab on the underlying HIV condition by describing changes in viral load, CD4 counts, incidence of opportunistic illnesses including the development of AIDS during and in the first year after CMT. 2) To evaluate the effect of CMT of anal cancer on anogenital HPV infection and anal cytology.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 具体目标： 主要目的：检测在标准放化疗中添加西妥昔单抗是否可以将局部失败率降低至少 50% 次要目标： 1) 通过描述 CMT 期间和之后第一年的病毒载量、CD4 计数、机会性疾病发生率（包括 AIDS 的发生）的变化来描述 CMT 加西妥昔单抗对潜在 HIV 状况的影响。 2)评价肛门癌CMT对肛门生殖器HPV感染和肛门细胞学的影响。